1-[2-(isoquinoline-5-sulfonamido)ethyl]guanidine hydrochloride

• ChemBase ID: 131572
• Molecular Formular: C12H16ClN5O2S
• Molecular Mass: 329.80574
• Monoisotopic Mass: 329.07132346
• SMILES: c1cc2cnccc2c(c1)S(=O)(=O)NCCNC(=N)N.Cl
• Canonical SMILES: NC(=N)NCCNS(=O)(=O)c1cccc2c1ccnc2.Cl
• InChI: InChI=1S/C12H15N5O2S.ClH/c13-12(14)16-6-7-17-20(18,19)11-3-1-2-9-8-15-5-4-10(9)11;/h1-5,8,17H,6-7H2,(H4,13,14,16);1H
• InChIKey: GUGJQAFPKZZOIV-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 1-[2-(isoquinoline-5-sulfonamido)ethyl]guanidine hydrochloride
• IUPAC Traditional name: 1-[2-(isoquinoline-5-sulfonamido)ethyl]guanidine hydrochloride
• Synonyms: N-(2-Guanidinoethyl)-5-isoquinolinesulfonamide hydrochloride; HA-1004 hydrochloride; N-[2-[(Aminoiminomethyl)amino]ethyl]-5-isoquinolinesulfonamide Monohydrochloride; HA 1004 Hydrochloride; N-(2-Guanidinoethyl)-5-isoquinolinesulfonamide Hydrochloride

Database IDs

• CAS Number: 92564-34-6
• MDL Number: MFCD00069285
• PubChem SID: 24895056; 162225850
• PubChem CID: 6917872

CALCULATED PROPERTIES

• Acid pKa: 10.048164
• H Acceptors: 6
• H Donor: 4
• LogD (pH = 5.5): -2.972689
• LogD (pH = 7.4): -2.8494208
• Log P: -0.9000623
• Molar Refractivity: 86.0703 cm^3
• Polarizability: 30.744589 Å^3
• Polar Surface Area: 120.96 Å^2
• Rotatable Bonds: 4
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: ethanol: soluble10 mg/mL; H2O: soluble10 mM; Water
• Apperance: White Crystalline Solid; white powder
• Melting Point: 235-236°C (dec.)

Safety Information

• Storage Condition: -20°C Freezer
• German water hazard class: 3
• Personal Protective Equipment: Eyeshields, Gloves, type N95 (US), type P1 (EN143) respirator filter
• Storage Temperature: -20°C

Product Information

• Purity: ≥98% (HPLC)

DETAILS

Sigma Aldrich - G1274

Biochem/physiol Actions
Shown to be an intracellular calcium antagonist. Reported to induce neurite formation.

Toronto Research Chemicals - G835000

A novel calcium antagonist and vasodilator with no effect on cardiac function.

REFERENCES

• Hidaka, H., et al.: J. of Pharm. and Exp. Therapeutics, 231, 1, 141 (1984)